国产新药闪耀ASCO2025，关注相关企业投资机遇

Investment Rating - The industry investment rating is "Outperform the Market" [5][37]. Core Viewpoints - The report highlights the significant presence of domestic innovative drugs at the 2025 ASCO conference, suggesting investment opportunities in related companies [5]. - The report emphasizes the increasing number of original research presentations by Chinese experts, with 71 studies selected for oral presentations, including 11 as late-breaking abstracts [5]. Summary by Sections Industry Overview - The 2025 ASCO conference will take place from May 30 to June 3 in Chicago, showcasing cutting-edge clinical oncology research and treatment technologies [5]. - Several domestic drugs have reported impressive clinical data, indicating a strong performance in the global oncology market [5]. Product Analysis - ZG005 by Zai Lab showed an objective response rate (ORR) of 69.2% and 80.0% for different dosage groups in advanced cervical cancer patients [6]. - The CAR-T therapy CT041 demonstrated a significant reduction in mortality risk by over 30% compared to standard treatment [6]. - TQB2102 for HER2 low-expressing breast cancer achieved an ORR of 53.4% in a study of 73 patients [6]. Investment Strategy - The report recommends focusing on "innovation," "going global," "equipment upgrades," and "consumption recovery" as key investment themes [8]. - Specific companies to watch include BeiGene, Dongcheng Pharmaceutical, and others in the innovative drug sector [8]. Market Performance - The pharmaceutical sector rose by 1.78% this week, outperforming the Shanghai Composite Index, which fell by 0.18% [11][36]. - The pharmaceutical industry ranked first in performance among 28 sectors this week [11][36].